Company intelligence / Profile preview

Biotrin

Dublin, Ireland

Ownership: Private
Employees: ~80
Development stage: Other

Overview

Biotrin is an Irish diagnostics company specializing in the development and commercialization of unique immunoassay products. The company is globally recognized for its leadership in Parvovirus B19 testing and its innovative biomarkers for monitoring organ damage, specifically Glutathione S-transferase (GST) for kidney and liver injury. Founded in Dublin, Biotrin established a strong presence in the niche diagnostic market before being acquired by the Italian diagnostics giant DiaSorin in 2008. Its products are used in clinical laboratories and by pharmaceutical companies for drug safety testing.

Therapeutic areas: GastroenterologyNephrologyInfectious Diseases
Modalities: Immunoassay
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Biotrin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotrin.

Explore the full profile